Page 79 - Read Online

Leung et al. J Transl Genet Genom 2023;7:79-86 https://dx.doi.org/10.20517/jtgg.2023.09 Page 73

Financial support and sponsorship
This work was supported by Health@InnoHK, Innovation and Technology Commission of the HKSAR,
Theme-based Research Scheme (T12-702/20-N), HMRF (08191906), Li Shu Fan Medical Foundation, Ying
Wan Leung Research Fund and Collaborative Research Fund (C7028-19G), and Tang King Ying Research
Fund.

Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Priestley P, Baber J, Lolkema MP, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature 2019;575:210-6. DOI
PubMed PMC
2. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine
fluorescence and Giemsa staining. Nature 1973;243:290-3. DOI
3. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia.
Lancet 1977;1:549-50. DOI PubMed
4. Döhner H, Wei AH, Löwenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol 2021;18:577-90. DOI PubMed
5. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J
Med 2008;358:1909-18. DOI
6. Cher CY, Leung GM, Au CH, et al. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT
activation loop and TET2 mutations predictive of outcome. Blood Cancer J 2016;6:e442. DOI PubMed PMC
7. Leung GMK, Zhang C, Ng NKL, et al. Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/
monosomy karyotype acute myeloid leukemia carrying TP53 mutations. Am J Hematol 2019;94:650-7. DOI
8. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N
Engl J Med 2017;377:454-64. DOI PubMed PMC
9. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with
acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014;15:986-96.
DOI PubMed PMC
10. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med
2020;383:617-29. DOI PubMed
11. Sakurai M, Oshimura M, Kakati S, Sandberg AA. Letter: 8-21 translocation and missing sex chromosomes in acute leukaemia. Lancet
1974;2:227-8. DOI PubMed
12. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international
expert panel on behalf of the ELN. Blood 2022;140:1345-77. DOI
13. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature
2008;456:66-72. DOI
14. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med
2009;361:1058-66. DOI
15. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo
cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:2348-55. DOI
PubMed PMC
16. DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J
Med 2018;378:2386-98. DOI PubMed
17. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood
2017;130:722-31. DOI
18. Tsui SP, Ip HW, Saw NY, et al. Redefining prognostication of de novo cytogenetically normal acute myeloid leukemia in young